Silence Therapeutics price target lowered to $26 from $29 at Chardan

Chardan analyst Keay Nakae lowered the firm’s price target on Silence Therapeutics to $26 from $29 and keeps a Buy rating on the shares after the company reported its FY22 results and updated on anticipated milestones for its two lead wholly-owned clinical programs: Zerlasiran, previously SLN360, targeting high Lp(a) and SLN124 targeting hepcidin. The firm’s lower target reflects adjustments to its model for SLN360 timing and future share count.